Smith & Nephew plc (SNN) Q2 2025 Earnings Call Transcript
Smith & Nephew plc (NYSE:SNN ) Q2 2025 Earnings Conference Call August 5, 2025 3:30 AM ET Company Participants Deepak S. Nath - CEO & Director John Terence Rogers - CFO & Executive Director Conference Call Participants David James Adlington - JPMorgan Chase & Co, Research Division Dylan van Haaften - Stifel, Nicolaus & Company, Incorporated, Research Division Graham Doyle - UBS Investment Bank, Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Jack Reynolds-Clark - RBC Capital Markets, Research Division Kane Slutzkin - Deutsche Bank AG, Research Division Richard Felton - Goldman Sachs Group, Inc., Research Division Robert John Davies - Morgan Stanley, Research Division Samuel England - Joh.
SNN or SYK: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Should Value Investors Buy Smith & Nephew SNATS (SNN) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SNN or ESLOY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Smith & Nephew (SNN) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks is more attractive to value investors?
Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SNN Expands Orthopedic Portfolio With Advanced Tibia Nailing System
Smith + Nephew launches TRIGEN MAX, the only tibia nailing system with side-specific nails for precise, low-impact fracture repair.
SNN vs. GEHC: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and GE HealthCare Technologies (GEHC). But which of these two stocks is more attractive to value investors?
Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Smith+Nephew Stock May Gain From Strategic Deal With Standard Health
SNN teams with Standard Health to launch the United Kingdom's first orthopedic ASC, aiming to boost surgical efficiency and drive growth.
Smith & Nephew plc (SNN) Q1 2025 Earnings Call Transcript
Smith & Nephew plc (NYSE:SNN ) Q1 2025 Results Conference Call April 30, 2025 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer Conference Call Participants Richard Felton - Goldman Sachs Julien Dormois - Jefferies Jack Reynolds-Clark - RBC Capital Markets Lisa Clive - Bernstein Hassan Al-Wakeel - Barclays Kane Slutzkin - Deutsche Bank David Adlington - JPMorgan Veronika Dubajova - Citi Dylan van Haaften - Stifel Robert Davies - Morgan Stanley Operator Ladies and gentlemen, welcome to the Smith & Nephew Q1 Trading Report. My name is Jenny, and I will be coordinating your call today.
Is Smith & Nephew SNATS (SNN) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Smith & Nephew: Underappreciated Recovery With Strategic Upside
Smith & Nephew is undergoing a turnaround under CEO Deepak Nath, focusing on margin expansion and growth through surgical robotics and regenerative technologies. Despite trading at a discount to peers, the company shows visible margin improvement, offering a compelling value proposition for investors. The base case projects 35% upside by 2025 with a 20% trading margin, while the bull case suggests 50-60% upside with further margin gains.
